An interventional study of NOVA DES in Intracranial Atherosclerotic Stenosis, sponsored by Sino Medical Sciences Technology Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Sino Medical Sciences Technology Inc. · Not applicable, Interventional, and Treatment
Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.
Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 10th largest by planned enrollment of the 56 interventional ones that give a count, is one of 12 that started in 2024, is one of 48 with no phase, reaches primary completion later than 13 of the 39 other live ones, and was the 64th registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 40+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Xin Lou · Sites in China
Ages 18–90
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 72 across 296 interventional studies indexed under Constriction, Pathologic.
Median enrollment 145 across the 56 interventional studies, 400 across the 25 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 81 have an industry lead sponsor. The 10 most frequent:
Sino Medical Sciences Technology Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sino Medical Sciences Technology Inc. has 1 study filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
15 of the studies in Constriction, Pathologic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197970Phase 3Beijing Tiantan HospitalDrug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis | 2027-05-15 |
| NCT07542938Xuanwu Hospital, BeijingMedeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis | 2026-11-30 |
| NCT07462546General Hospital of Shenyang Military RegionTranscranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) | 2026-11-30 |
| NCT06503692DK Medical Technology (Suzhou) Co., Ltd.Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis | 2026-12 |
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
Add all 15 to your calendar (.ics) → With an account.
Among the 81 studies in Constriction, Pathologic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to evaluate the Safety, Efficacy, and Standardized Procedural Optimization of the Intracranial Drug-Eluting Stent System in Patients with Symptomatic Intracranial Atherosclerotic Stenosis.
The investigation is a prospective, multi-center clinical study. The trial is expected to enroll 300 subjects. The population for this study is subjects with intracranial atherosclerotic stenosis who are suitable candidates for stent angioplasty. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be enrolled after they signed the informed consent form. The study consists of ten visits including preoperative screening, procedure date, 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years. The primary endpoints are stroke or death within 30 days after enrollment, plus any ischemic stroke or revascularization from the original culprit intracranial artery beyond 30 days through 12 months after procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who met the inclusion criteria were implanted with the NOVA stent, and the procedure was documented in detail.
Device: NOVA DES
The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
Stroke or death within 30 days after enrollment, plus any ischemic stroke or revascularization from the original culprit intracranial artery beyond 30 days through 12 months after procedure.
This outcome includes ischemic/hemorrhagic stroke and all-cause death within 30 days after procedure of the qualifying lesion during follow-up, or any ischemic stroke and revascularization from the original culprit symptomatic intracranial artery beyond 30 days through 12 months after procedure.
Time frame: 1 year after procedure
Rate of any stroke (hemorrhagic/ischemic stroke) in the target blood supply area or all-cause death at 30 days after procedure
The rate of Hemorrhagic stroke as well as symptomatic ischemic stroke and any death in the target blood supply area
Time frame: 30 days after procedure
Rate of any stroke (hemorrhagic/ischemic stroke) in the non-target blood supply area or all-cause death at 30 days after procedure
The rate of Hemorrhagic stroke as well as symptomatic ischemic stroke and any death in the non-target blood supply area
Time frame: 30 days after procedure
Rate of TIA at 30 days, 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
TIA is a temporary blockage of blood flow to the brain with symptoms last from only a few minutes up to 24 hours
Time frame: 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
Rate of any stroke (hemorrhagic/ischemic stroke) in the target blood supply area at 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
The rate of Hemorrhagic stroke as well as symptomatic ischemic stroke in the target blood supply area
Time frame: 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
Rate of any stroke (hemorrhagic/ischemic stroke) in the non-target blood supply area at 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
The rate of Hemorrhagic stroke as well as symptomatic ischemic stroke in the non-target blood supply area
Time frame: 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
Rate of death (vascular/ non-vascular death) at 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
The cause of death was classified as vascular or nonvascular and based on information obtained from the family, medical records, and death certificates. Vascular death included death due to stroke, MI, heart failure, pulmonary embolus, cardiac arrhythmia, or other vascular cause.
Time frame: 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
Rate of symptomatic ISR and Revascularization at 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
symptomatic ISR is defined as ISR associated with an ischemic event in the territory. Revascularization is the restoration or improvement of blood supply, and included surgical operation, endovascular procedures, etc.
Time frame: 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
Rate of modified Rankin Scale (mRS) at 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death.
Time frame: 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
EQ-5D score at 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
A health state defined by the descriptive EQ-5D system can be described by a five-digit number, each digit indicating the score of the corresponding dimension.
Time frame: 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years after procedure
Rate of in-stent restenosis at 1, 2, 3, 4 years and 5 years after procedure (Optional)
Patients with ≥50% stenosis of the vessel
Time frame: 1, 2, 3, 4 years and 5 years after procedure
Rate of Device defect
Device defects refer to the unreasonable risks that may endanger human health and life safety during the normal use of medical devices in the course of clinical trials, such as label errors, quality problems, failures, etc.
Time frame: within 5 years of whole trial
Rate of bleeding events at 1 years after procedure
Bleeding was defined according to Bleeding Academic Research Consortium
Time frame: 1 year after procedure
Started Mar 2024 (actual). Primary completion is estimated for Jun 2026, 27 months after the start.
Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 27 months is below that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sino Medical Sciences Technology Inc.